10
Grouping & Discussion Obaid Ali Civil Service Officer, Member, ISPE, PDA 26 March 2017

6 OARO - ICH Grouping & Discussion

Embed Size (px)

Citation preview

Page 1: 6 OARO - ICH Grouping & Discussion

Grouping & Discussion

Obaid AliCivil Service Officer, Member, ISPE, PDA

26 March 2017

Page 2: 6 OARO - ICH Grouping & Discussion

Not the view of DRAP

Current judgment

No obligation on DRAP

Regulatory experience

D

I

S

C

L

A

I

M

E

R

References US-FDA WHO ICH NRAs

Page 3: 6 OARO - ICH Grouping & Discussion

Phenomenon 1

Page 4: 6 OARO - ICH Grouping & Discussion

Shelf life was reduced to 15

months from 18 months

Adjustment was due to results

of three validation batches

Is it correct to determine

the expiration dates? ?

Projected

Failed in 11

lots

Rationale

Page 5: 6 OARO - ICH Grouping & Discussion

Is it correct to

determine

the expiration

dates?

Yes/ No

Page 6: 6 OARO - ICH Grouping & Discussion

NO

Because

It is not a minor, but a significant issue (11 lots)

Trust is lost about strength, quality & purity at the

time of use

Root cause & rationale of decision is missing

Page 7: 6 OARO - ICH Grouping & Discussion

Remember

to reportEvery stability failure to Regulatory Authority

within timeframe

No matter if test is conducted after the expiry

of final stability time point

Page 8: 6 OARO - ICH Grouping & Discussion

Phenomenon 2

Page 9: 6 OARO - ICH Grouping & Discussion

Representative

Can a filled vial be used as representative sample of drum

if both are shipped together in same environment?

Page 10: 6 OARO - ICH Grouping & Discussion

No